688180 君实生物
2026/06 - 中期
人民币(K¥)
2025/12
人民币(K¥)
2024/12
人民币(K¥)
2023/12
人民币(K¥)
2022/12
人民币(K¥)
经营活动产生之现金流量净额(68,562)(519,568)(1,433,841)(2,004,982)(1,776,201)
投资活动产生之现金流量净额(1,438,365)(1,580,711)(892,782)(933,191)(437,213)
筹资活动产生之现金流量净额1,644,4132,229,3061,023,146711,8284,613,478
汇率变动对现金及现金等价物的影响(25,543)(21,707)12,0157,55192,266
现金及现金等价物净增加/(减少)111,943107,321(1,291,463)(2,218,794)2,492,331
期初现金及现金等价物余额2,594,0002,486,6793,778,1425,996,9363,504,605
期末现金及现金等价物余额2,705,9432,594,0002,486,6793,778,1425,996,936